RecruitingNCT06081231

Open-Source Artificial Pancreas System Use Among People With Type 1 Diabetes Mellitus in China

The Safety and Efficacy of Open-Source Artificial Pancreas System Among People With Type 1 Diabetes Mellitus in China

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Enrollment

500 participants

Start Date

Jan 1, 2019

Study Type

OBSERVATIONAL

Conditions

Type 1 Diabetes Mellitus

Summary

This real-world observational study aims to reveal the current status of the open-source artificial pancreas system (APS) use among people with T1DM in China and assess the glycemic efficacy and potential related factors of the open-source APS.

Eligibility

Min Age: 3 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study surveys people with Type 1 diabetes in China who are using open-source artificial pancreas systems — automated devices that continuously monitor blood sugar and adjust insulin delivery. Researchers want to understand how these systems are being used in real-world settings. **You may be eligible if...** - You have been diagnosed with Type 1 diabetes - You have been using an open-source artificial pancreas system for at least 3 months - You currently live in China - You are willing to share your data and provide informed consent (parents or guardians may consent on behalf of minors) **You may NOT be eligible if...** - There are no stated exclusion criteria Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.